| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
PF-07104091 (PF07104091) is a novel and orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2) with potential anticancer activity. PF-07104091 exhibits selectivity against CDK1 of 100 fold, selectivity against CDK4 and CDK6 of 200 to 400 fold, selectivity against CDK9 of 170 fold, and selectivity against GSK3B of more than 500 fold. The single-agent PF-07104091 showed dose-dependent tumor growth reduction with 86 percent maximal effect in a study on tumor growth inhibition in an ovarian cancer model. It also showed single-agent efficacy in multiple ovarian models. Additionally, PF-07104091 restored cell-cycle control in cancer types unresponsive to CDK4/6 inhibitors. In a phase I/IIa dose escalation trial, PF-07104091 is presently being tested; the first patient will receive a dose in October 2020. It is possible to treat cyclinE-amplified cancers with PF-07104091. One of the many cyclin-dependent kinases, CDK2, needs to bind to a regulatory cyclin subunit, like A or E.
| Targets |
CDK2
|
|---|---|
| References | |
| Additional Infomation |
Tagtociclib is an orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, tagtociclib selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition.
|
| Molecular Formula |
C19H28N6O4
|
|---|---|
| Molecular Weight |
404.463423728943
|
| Exact Mass |
404.217
|
| Elemental Analysis |
C, 56.42; H, 6.98; N, 20.78; O, 15.82
|
| CAS # |
2460249-19-6
|
| Related CAS # |
2460249-19-6
|
| PubChem CID |
154616422
|
| Appearance |
Solid powder
|
| LogP |
1.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
29
|
| Complexity |
577
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)NC(=O)O[C@@H]1CC[C@@H](C1)C2=CC(=NN2)NC(=O)C3=CC(=NN3C)COC
|
| InChi Key |
MTNBRBDFNSGQKB-GXTWGEPZSA-N
|
| InChi Code |
InChI=1S/C19H28N6O4/c1-11(2)20-19(27)29-14-6-5-12(7-14)15-9-17(23-22-15)21-18(26)16-8-13(10-28-4)24-25(16)3/h8-9,11-12,14H,5-7,10H2,1-4H3,(H,20,27)(H2,21,22,23,26)/t12-,14+/m0/s1
|
| Chemical Name |
[(1R,3S)-3-[3-[[5-(methoxymethyl)-2-methylpyrazole-3-carbonyl]amino]-1H-pyrazol-5-yl]cyclopentyl] N-propan-2-ylcarbamate
|
| Synonyms |
tagtociclib; PF-07104091; PF-7104091; PF 07104091; PF 7104091; PF07104091; PF7104091
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~81 mg/mL (~200.3 mM)
Ethanol: ~41 mg/mL (~101.4 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4724 mL | 12.3622 mL | 24.7243 mL | |
| 5 mM | 0.4945 mL | 2.4724 mL | 4.9449 mL | |
| 10 mM | 0.2472 mL | 1.2362 mL | 2.4724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04553133 | Recruiting | Drug: PF-07104091 + Fulvestrant (post CDK4/6) Drug: PF-0704091 + Fulvestrant (post CDK4/6) |
Breast Cancer Ovarian Cancer |
Pfizer | September 16, 2020 | Phase 1 Phase 2 |
| NCT05262400 | Recruiting | Drug: PF-07220060 + PF-07104091 combination dose escalation Drug: PF-07104091 + PF-07220060 + letrozole dose expansion |
Breast Cancer Solid Tumors |
Pfizer | March 14, 2022 | Phase 1 Phase 2 |
| NCT05431153 | Completed | Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) |
Healthy | Pfizer | June 10, 2022 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
